Albuterol Sulfate Metered Dose Inhalers Market Report 2026

The albuterol sulfate metered dose inhalers market size has grown strongly in recent years. It will grow from $5.15 billion in 2025 to $5.57 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to CFC inhaler phase-out, asthma prevalence growth, hospital respiratory care adoption, inhaler portability demand, regulatory compliance.

The albuterol sulfate metered dose inhalers market size is expected to see strong growth in the next few years. It will grow to $7.61 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to eco-friendly inhaler development, chronic respiratory disease growth, homecare inhaler usage, patient-centric device design, generic inhaler approvals. Major trends in the forecast period include shift toward hydrofluoroalkane-based inhalers, rising use of portable respiratory devices, expansion of breath-activated inhalers, growth of generic metered dose inhalers, increased focus on patient adherence.

The increasing prevalence of respiratory conditions is expected to drive the growth of the albuterol sulfate metered-dose inhalers market in the coming years. Respiratory conditions are diseases that affect the lungs and airways, causing difficulty in breathing and reduced oxygen intake. These include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and other lung infections. The growing prevalence of respiratory conditions is attributed to rising air pollution, which increases exposure to harmful pollutants that irritate the airways and impair lung function. Albuterol sulfate metered-dose inhalers relieve symptoms of respiratory conditions by relaxing airway muscles, enhancing airflow, and making breathing easier. They rapidly reduce wheezing, coughing, and shortness of breath, providing immediate relief. For example, in June 2025, according to the World Health Organization, a Switzerland-based organization, 81.7 million people are living with chronic respiratory diseases, and 6.8 million are newly diagnosed each year. Therefore, the increasing prevalence of respiratory conditions drives the growth of the albuterol sulfate metered-dose inhalers market.

Major companies operating in the albuterol sulfate metered-dose inhalers market are concentrating on developing advanced offerings, such as generic inhalation products, to enhance accessibility for patients with chronic respiratory conditions. Generic inhalation products are non-branded versions of inhaled medications that contain the same active ingredients, dosage, and therapeutic effects as their branded equivalents, usually at a lower cost. For example, in May 2024, Amphastar Pharmaceuticals Inc., a US-based pharmaceutical company, received abbreviated new drug application (ANDA) approval from the Food and Drug Administration (FDA) for Albuterol Sulfate inhalation aerosol for the treatment or prevention of bronchospasm in patients aged four years and older. Albuterol sulfate inhalation aerosol functions by relaxing the airway muscles to open them and improve airflow, offering rapid relief from symptoms such as wheezing and shortness of breath in conditions like asthma.

In May 2024, Bespak, a UK-based pharmaceutical device manufacturer, formed a partnership with DevPro to develop an albuterol metered-dose inhaler (MDI) using HFO-1234ze propellant. Through this collaboration, Bespak aims to promote environmentally sustainable respiratory device solutions by leveraging DevPro's expertise in low-global-warming-potential propellants, broadening its range of eco-friendly inhalation products, and supporting the pharmaceutical industry's shift away from high-global-warming-potential propellants. DevPro is a US-based contract development and manufacturing organization focused on creating MDI products with next-generation propellant technologies.

Major companies operating in the albuterol sulfate metered dose inhalers market are Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Cipla Limited, Lupin Limited, Zydus Pharmaceuticals Inc., Viatris Inc., Mylan N.V., Amneal Pharmaceuticals Inc., Perrigo Company plc, Prasco Laboratories, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Apotex Inc., Accord Healthcare Limited, Intas Pharmaceuticals Ltd., Chiesi Farmaceutici S.p.A., Nephron Pharmaceuticals Corporation.

North America was the largest region in the albuterol sulfate metered dose inhalers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albuterol sulfate metered dose inhalers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the albuterol sulfate metered dose inhalers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the albuterol sulfate metered dose inhalers market by increasing the cost of imported propellants, device components, and pharmaceutical grade aluminum canisters used in pressurized inhaler production. These impacts have been most pronounced in pressurized inhaler segments, where device precision and regulatory compliance are critical. Regions such as North America and Europe have experienced higher input costs due to reliance on globally sourced inhaler components, while Asia Pacific manufacturers have faced component supply disruptions. Rising tariff related expenses have influenced pricing strategies, procurement planning, and production scheduling. However, tariffs have supported domestic inhaler manufacturing, localized device assembly, and stronger long term supply chain resilience.

The albuterol sulfate metered dose inhalers market research report is one of a series of new reports that provides albuterol sulfate metered dose inhalers market statistics, including albuterol sulfate metered dose inhalers industry global market size, regional shares, competitors with a albuterol sulfate metered dose inhalers market share, detailed albuterol sulfate metered dose inhalers market segments, market trends and opportunities, and any further data you may need to thrive in the albuterol sulfate metered dose inhalers industry. This albuterol sulfate metered dose inhalers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Albuterol sulfate metered dose inhalers (MDIs) are compact devices created to administer an exact dose of albuterol sulfate directly into the lungs. They aid in relaxing airway muscles, enhancing airflow, and providing rapid relief from breathing difficulties. Albuterol sulfate metered dose inhalers are primarily used for controlling and easing symptoms linked to respiratory conditions.

The primary product types of albuterol sulfate metered dose inhalers include pressurized metered dose inhalers (pMDIs) and breath-activated metered dose inhalers. Pressurized metered-dose inhalers (pMDIs) are portable devices that deliver a precise aerosolized dose of medication to the lungs, providing rapid relief for respiratory conditions. They are available in various formulations, such as single-unit dose inhalers and multiple-unit dose inhalers, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, for different applications, including asthma, chronic obstructive pulmonary disease (COPD), and more.

The albuterol sulfate metered dose inhalers market consists of sales of dry powder inhalers (DPIs), soft mist inhalers (SMIs), nebulizers, and aerosol Inhalers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.